76.99  0 (0%)		08-27 16:00
Open: 76.97 High: 76.99 Volume: 0		Pre. Close: 76.99 Low: 76.97 Market Cap: 1,634(M)

Short term
Mid term
Targets	6-month :	90.16	1-year :	105.31
Resists	First :	77.19	Second :	90.16
Pivot price	76.9
Supports	First :	76.69	Second :	76.37
MAs	MA(5) :	76.97	MA(20) :	76.84
	MA(100) :	39.68	MA(250) :	28.85
MACD	MACD :	5.2	Signal :	6.9
%K %D	K(14,3) :	96	D(3) :	96.8
RSI	RSI(14): 84.3
52-week	High :	77.19	Low :	10.1

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FBRX ] has closed below upper band by 15.5%. Bollinger Bands are 98.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	77.08 - 77.38	77.38 - 77.65
Low:	76.13 - 76.51	76.51 - 76.84
Close:	76.33 - 76.95	76.95 - 77.49

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Tue, 11 Aug 2026
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences - Yahoo Finance

Tue, 11 Aug 2026
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX - Business Wire

Tue, 28 Jul 2026
Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears - Yahoo Finance

Mon, 27 Jul 2026
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx - Yahoo Finance

Mon, 27 Jul 2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline - GlobeNewswire

Mon, 27 Jul 2026
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	21 (M)
Shares Float	19 (M)
Held by Insiders	1.6 (%)
Held by Institutions	96.6 (%)
Shares Short	1,630 (K)
Shares Short P.Month	2,060 (K)

EPS	-4.58
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.51
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-37.8 %
Return on Equity (ttm)	-62.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.47
Qtrly Earnings Growth	0 %
Operating Cash Flow	-72 (M)
Levered Free Cash Flow	-41 (M)

PE Ratio	-16.85
PEG Ratio	0
Price to Book value	10.23
Price to Sales	0
Price to Cash Flow	-22.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.